BioCryst Pharmaceuticals Inc. (BCRX) Financial Statements (2024 and earlier)

Company Profile

Business Address 4505 EMPEROR BOULEVARD
DURHAM, NC 27703
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments388,987424,310507,601300,366136,226104,467
Cash and cash equivalents110,643304,767504,389272,127114,17226,731
Short-term investments278,344119,5433,21228,23922,05477,736
Restricted cash and investments1,8041,4723,3452,2211,5511,544
Receivables2,2968,2681,9808,24322,1464,293
Inventory, net of allowances, customer advances and progress billings28,68327,53315,7917,039 1,649
Inventory28,68327,53315,7917,039 1,649
Deferred costs      9
Other undisclosed current assets74,19654,91737,4195,9314,4222,390
Total current assets:495,966516,500566,136323,800164,345114,352
Noncurrent Assets
Property, plant and equipment7,9108,6178,7147,1137,3479,135
Long-term investments and receivables  18,0776,829  22,376
Long-term investments  18,0776,829  22,376
Other noncurrent assets13,0846,8066,4723,8023,590978
Total noncurrent assets:20,99433,50022,01510,91510,93732,489
TOTAL ASSETS:516,960550,000588,151334,715175,282146,841
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities123,775101,921100,47874,32550,25735,508
Interest and dividends payable 21,67014,90411,848
Accounts payable20,89314,35627,80818,71313,9887,769
Accrued liabilities102,88287,56572,67033,94221,36515,891
Deferred revenue  1,2241,4211502,120
Debt1,590  31,17939,95833,748
Other undisclosed current liabilities24,6232,3691,819  221
Total current liabilities:149,988105,514103,718105,65492,33569,477
Noncurrent Liabilities
Long-term debt and lease obligation306,076231,624142,044123,6063,406 
Long-term debt, excluding current maturities303,231231,624136,082119,735  
Finance lease, liability2,845  3,8713,406
Liabilities, other than long-term debt8,3905,804   54
Deferred rent credit      54
Operating lease, liability8,3905,8045,962  
Total noncurrent liabilities:314,466237,428148,006123,6063,40654
Total liabilities:464,454342,942251,724229,26095,74169,531
Equity
Equity, attributable to parent(455,528)(294,597)(106,986)(19,262)38,25249,235
Common stock2,0581,8791,8431,7691,5411,101
Additional paid in capital1,222,2361,158,1181,098,4981,002,408877,300780,400
Accumulated other comprehensive income (loss)1,33726177339(297)
Accumulated deficit(1,681,159)(1,454,620)(1,207,504)(1,023,442)(840,628)(731,969)
Total equity:(455,528)(294,597)(106,986)(19,262)38,25249,235
Other undisclosed liabilities and equity508,034501,655443,413124,71741,28928,075
TOTAL LIABILITIES AND EQUITY:516,960550,000588,151334,715175,282146,841

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues331,412270,827157,17017,81248,83520,653
Cost of revenue(4,661)(6,594)(7,264)(1,550)(3,726) 
Cost of goods and services sold(4,481)(6,408)(7,229)(1,550)(3,726) 
Gross profit:326,751264,233149,90616,26245,10920,653
Operating expenses(430,460)(412,668)(327,626)(191,019)(144,564)(114,873)
Operating loss:(103,709)(148,435)(177,720)(174,757)(99,455)(94,220)
Interest and debt expense(137,258)(99,092)(3,456)(16,512)(11,892)(9,176)
Other undisclosed income from continuing operations before equity method investments, income taxes    8,455  
Loss from continuing operations before equity method investments, income taxes:(240,967)(247,527)(181,176)(182,814)(111,347)(103,396)
Other undisclosed income (loss) from continuing operations before income taxes14,7383,144(633)   
Loss from continuing operations before income taxes:(226,229)(244,383)(181,809)(182,814)(111,347)(103,396)
Income tax expense(310)(2,733)(2,253)   
Loss from continuing operations:(226,539)(247,116)(184,062)(182,814)(111,347)(103,396)
Loss before gain (loss) on sale of properties:(184,062)(182,814)(111,347)(103,396)
Net loss:(226,539)(247,116)(184,062)(182,814)(111,347)(103,396)
Other undisclosed net income attributable to parent     2,4502,144
Net loss available to common stockholders, diluted:(226,539)(247,116)(184,062)(182,814)(108,897)(101,252)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(226,539)(247,116)(184,062)(182,814)(111,347)(103,396)
Other comprehensive income (loss)1,311(151)174(36)336(54)
Other undisclosed comprehensive income      
Comprehensive loss:(225,228)(247,267)(183,888)(182,850)(111,011)(103,450)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    2,4502,144
Comprehensive loss, net of tax, attributable to parent:(225,228)(247,267)(183,888)(182,850)(108,561)(101,306)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: